Land: Kanada
Sprache: Englisch
Quelle: Health Canada
NELFINAVIR (NELFINAVIR MESYLATE)
PFIZER CANADA ULC
J05AE04
NELFINAVIR
250MG
TABLET
NELFINAVIR (NELFINAVIR MESYLATE) 250MG
ORAL
270/300
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0134340001; AHFS:
CANCELLED POST MARKET
2022-06-02
_VIRACEPT _ _®_ _ (nelfinavir mesylate) Product Monograph _ _Page 1 of 45_ _ _ PRODUCT MONOGRAPH PR VIRACEPT ® Nelfinavir tablets, 250 mg, 625 mg (as nelfinavir mesylate) Nelfinavir powder, 50 mg/g (as nelfinavir mesylate) HIV PROTEASE INHIBITOR Pfizer Canada Inc. Date of Revision: 17, 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 28 October 2016 Dist. by: ViiV Healthcare ULC Montreal, Quebec H4S 1Z1 Control No. 197422 ® Agouron Pharmaceuticals, Inc. Pfizer Canada Inc., Licensee © Pfizer Canada Inc. 2016 _VIRACEPT _ _®_ _ (nelfinavir mesylate) Product Monograph _ _Page 2 of 45_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS .................................................................................................. 11 DOSAGE AND ADMINISTRATION .............................................................................. 24 OVERDOSAGE ................................................................................................................ 25 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 26 STORAGE AND STABILITY .......................................................................................... 28 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 28 PART II: SCIENTIFIC INFORMATION ............................................................................... 29 P Lesen Sie das vollständige Dokument